Lilly (Eli) (LLY) Q1 2025 10-Q Quarterly Report
Lilly (Eli) (LLY) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on May 1, 2025 for the fiscal period ending Mar 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Lilly (Eli) Q1 2025 10-Q Analysis
Management Discussion & Analysis
- • Cash and cash equivalents $3.09B as of Mar 31, 2025 vs $3.27B Dec 31, 2024
- • Total debt $38.52B up $4.87B from $33.64B Dec 31, 2024, driven by $6.5B notes issued and Scorpion acquisition
- • Share repurchases $1.20B executed in Q1 2025 under $15B program, $13.80B remaining
- • Dividends paid $1.35B or $1.50/share in Q1 2025
- • Capital expenditures increasing due to global manufacturing investments and contract manufacturing agreements up to $8B potential liability
Risk Factors
- • New acquisition risk: $1,571.7 million acquired IPR&D charge from Scorpion PI3Kα inhibitor program STX-478 acquisition
- • Updated tax risk: effective tax rate increased to 20.2% from 11.6%, driven by non-deductible acquired IPR&D charge
- • Regulatory/legal risk: amendment with Boehringer Ingelheim caused $370 million one-time Jardiance collaboration benefit
- • Operational risk: marketing expenses up 26% driven by promotion of ongoing and future product launches impacting near-term costs
- • Financial risk: strong liquidity supported by cash, cash equivalents, operating cash flow, and access to borrowings to fund capital needs
Lilly (Eli) Q1 2025 Quarterly FinancialsXBRL
Revenue
$12.7B
▲ +45.2% YoY
Net Income
$2.8B
▲ +23.0% YoY
Net Margin
21.7%
▼ -390bp YoY
Source: XBRL data from Lilly (Eli) Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Lilly (Eli) Quarterly Reports
Get deeper insights on Lilly (Eli)
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.